Overcoming Drug Resistance in Multiple Myeloma

克服多发性骨髓瘤的耐药性

• 批准号: 10414667
• 负责人: Peter Leif Bergsagel
• 金额: $ 8.33万
• 依托单位: MAYO CLINIC ARIZONA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10414667
• 关键词: Animal Model; Bone Marrow; Cell Line; Cells; Clinic; Clustered Regularly Interspaced Short Palindromic Repeats; Collaborations; Dependence; Disease; Drug resistance; Immunomodulators; Malignant - descriptor; Malignant Neoplasms; Mediating; Membrane Proteins; Minnesota; Multiple Myeloma; Pathogenicity; Patients; Pharmaceutical Preparations; Proteasome Inhibitor; Resistance; Resources; Role; Sampling; T-Lymphocyte; Universities; glycosylation; in vivo; tumor; tumor microenvironment

This supplement will allow the Mayo Clinic/University of Minnesota Myeloma DRSC to provide unique resources and support to Dr. Constantine Mitsiades’ supplement to his U01. Dr. Mitsiades is studying the role of glycosylation in drug resistance and in collaboration with the DRSC will analyze myeloma cell lines and drug refractor patient samples for alterations in glycosylation. In addition, the DRSC will provide a unique animal model of myeloma that will be used for in vivo selection of CRISPR targets that mediate drug resistance to immunomodulatory drugs, proteasome inhibitors and T-cell engagers.

该补充品将使梅奥诊所/明尼苏达大学骨髓瘤 DRSC 能够提供独特的 Constantine Mitsiades 博士对其 U01 的补充提供资源和支持。 Mitsiades 博士正在研究这个角色 糖基化在耐药性中的作用，并与 DRSC 合作将分析骨髓瘤细胞系和药物 验光患者样本中糖基化的改变。此外，DRSC还将提供一种独特的动物 骨髓瘤模型将用于体内选择介导耐药性的 CRISPR 靶点 免疫调节药物、蛋白酶体抑制剂和 T 细胞接合剂。

项目成果

Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.

• DOI: 10.1158/2643-3230.bcd-23-0062
• 发表时间: 2024-01-08
• 期刊: Blood cancer discovery
• 影响因子: 11.2

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.

• DOI: 10.1158/2643-3230.bcd-23-0061
• 发表时间: 2024-01-08
• 期刊: Blood cancer discovery
• 影响因子: 11.2

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup.

• DOI: 10.3390/life12060812
• 发表时间: 2022-05-30
• 期刊: LIFE-BASEL
• 影响因子: 3.2
• 作者: Wiedmeier-Nutor, Julia Erin;Bergsagel, Peter Leif
• 通讯作者: Bergsagel, Peter Leif

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma.

• DOI: 10.1038/s41408-023-00851-5
• 发表时间: 2023-05-22
• 期刊: BLOOD CANCER JOURNAL
• 影响因子: 12.8
• 作者: Baughn, Linda B. B.;Jessen, Erik;Sharma, Neeraj;Tang, Hongwei;Smadbeck, James B. B.;Long, Mark D. D.;Pearce, Kathryn;Smith, Matthew;Dasari, Surendra;Sachs, Zohar;Linden, Michael A. A.;Cook, Joselle;Stewart, A. Keith;Chesi, Marta;Mitra, Amit;Bergsagel, P. Leif;Van Ness, Brian;Kumar, Shaji K. K.
• 通讯作者: Kumar, Shaji K. K.

Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.

• DOI: 10.1158/1541-7786.mcr-19-1026
• 发表时间: 2020-10
• 期刊: Molecular cancer research : MCR
• 作者: Shi CX;Zhu YX;Bruins LA;Bonolo de Campos C;Stewart W;Braggio E;Stewart AK
• 通讯作者: Stewart AK